Skip to main content
SpringerLink
Log in

Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment

  • Review Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Botulinum toxin type A (BoNT-A) is considered the gold standard for the treatment of focal post-stroke spasticity (PSS). However, a recently published study estimated that a significant percentage of patients affected by PSS could benefit from higher doses of BoNT-A than those permitted by current directives in the countries studied. Several studies have reported the use of high doses of BoNT-A in the management of patients affected by severe PSS; however, the most important adverse effect of this drug might be systemic diffusion of the toxin, which could potentially be related to its dose. Even if systemic toxicity is a rare event, fear of systemic toxicity is still the most relevant concern regarding use of high doses. The aim of our narrative review was to show the state of the art on the use of high doses of BoNT-A in patients affected by PSS in order to define the safety profile, focusing on both clinical and instrumental assessment of systemic effects. Current evidence from the literature suggests that higher doses of BoNT-A are effective in reducing spasticity of upper and lower limbs after stroke, with rare occurrence of mild adverse effects. The use of high doses seems to be an effective and safe therapeutic option to reduce multifocal or generalized PSS in selected patients. In particular, the potential role of higher doses in order to improve the functional outcome of these patients should be noted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke. 2010;41(2):319–24.

    Article  PubMed  Google Scholar 

  2. Wissel J, Manack A, Brainin M. Toward an epidemiology of post stroke spasticity. Neurology. 2013;80(3 Suppl 2):S13–9.

    Article  PubMed  Google Scholar 

  3. Denno MS, Gillard PJ, Graham GD, DiBonaventura MD, Goren A, Varon SF, et al. Anxiety and depression associated with caregiver burden in caregivers of stroke survivors with spasticity. Arch Phys Med Rehabil. 2013;94(9):1731–6.

    Article  PubMed  Google Scholar 

  4. Santamato A, Micello MF, Ranieri M, Valeno G, Albano A, Baricich A, et al. Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke. J Neurol Sci. 2015;350(1–2):1–6.

    Article  CAS  PubMed  Google Scholar 

  5. Santamato A, Panza F. Benefits and risks of non-approved injection regimens for botulinum toxins in spasticity. Drugs. 2017;77(13):1413–22.

    Article  CAS  PubMed  Google Scholar 

  6. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13–25.

    Article  PubMed  Google Scholar 

  7. Picelli A, Baricich A, Cisari C, Paolucci S, Smania N, Sandrini G. The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A. Funct Neurol. 2017;32(2):89–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Baricich A, Grana E, Carda S, Santamato A, Cisari C, Invernizzi M. High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis. J Neural Transm (Vienna). 2015;122(9):1283–7.

    Article  CAS  PubMed  Google Scholar 

  9. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle Nerve. 1987;10(6):552–5 (Erratum in: Muscle Nerve. 1988;11(5):520).

    Article  CAS  PubMed  Google Scholar 

  10. Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1–2):2–6.

    Article  CAS  PubMed  Google Scholar 

  11. Thibaut A, Chatelle C, Ziegler E, Bruno MA, Laureys S, Gosseries O. Spasticity after stroke: physiology, assessment and treatment. Brain Inj. 2013;27(10):1093–105.

    Article  PubMed  Google Scholar 

  12. Esquenazi A, Alfaro A, Ayyoub Z, Charles D, Dashtipour K, Graham GD, et al. OnabotulinumtoxinA for lower limb spasticity: guidance from a Delphi Panel approach. PM R. 2017;9(10):960–8.

    Article  PubMed  Google Scholar 

  13. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167–93.

    Article  CAS  PubMed  Google Scholar 

  14. Humeau Y, Doussau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie. 2000;82:427–46.

    Article  CAS  PubMed  Google Scholar 

  15. Franceschini M, Iocco M, Molteni F, Santamato A, Smania N, Italian Spasticity Study Group. Management of stroke patients submitted to botulinum toxin type A therapy: a Delphi survey of an Italian expert panel of specialist injectors. Eur J Phys Rehabil Med. 2014;50(5):525–33.

    CAS  PubMed  Google Scholar 

  16. Baker JA, Pereira G. The efficacy of botulinum toxin A for spasticity and pain in adults: a systematic review and meta-analysis using the Grades of Recommendation, Assessment, Development and Evaluation approach. Clin Rehabil. 2013;27(12):1084–96.

    Article  PubMed  Google Scholar 

  17. Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Dressler D, Adib Saberi F, Kollewe K, Schrader C. Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm. 2015;122(2):327–33.

    Article  CAS  PubMed  Google Scholar 

  19. Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J. An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport). BMJ Open. 2013. https://doi.org/10.1136/bmjopen-2012-001853.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Rychlik R, Kreimendahl F, Schnur N, Lambert-Baumann J, Dressler D. Quality of life and costs of spasticity treatment in German stroke patients. Health Econ Rev. 2016;6(1):27.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl. 5):21–9.

    Article  PubMed  Google Scholar 

  22. Sesardic D, Leung T, Gaines-Das R. Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum type A toxin. Biologicals. 2003;3:265–76.

    Article  CAS  Google Scholar 

  23. McLellan K, Das RE, Ekong TA, Sesardic D. Therapeutic botulinum type A toxin: factors affecting potency. Toxicon. 1996;34:975–85.

    Article  CAS  PubMed  Google Scholar 

  24. Chen JJ, Dashtipour K. Abo-, Inco-, Ona-, and Rima-Botulinum toxins in clinical therapy: a primer. Pharmacotherapy. 2013;33:304–18.

    Article  CAS  PubMed  Google Scholar 

  25. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15(1):1–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64:1949–51.

    Article  CAS  PubMed  Google Scholar 

  27. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S, NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–12.

    Article  CAS  PubMed  Google Scholar 

  28. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers. J Neural Transm. 2005;112:905–13.

    Article  CAS  PubMed  Google Scholar 

  29. Park J, Lee MS, Harrison AR. Profile of Xeomin (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophtalmol. 2011;5:725–32.

    CAS  Google Scholar 

  30. Zoons E, Dijkgraaf MGW, Dijk JM, van Schaik IN, Tijssen MA. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol. 2012;259:2519–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761–8.

    Article  PubMed  Google Scholar 

  32. Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay. J Neural Transm. 2012;119:13–5.

    Article  CAS  PubMed  Google Scholar 

  33. Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H. Botulinum A toxins: units versus units. Arch Pharmacol. 1997;355:335–40.

    Article  CAS  Google Scholar 

  34. Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord. 2005;20:937–44.

    Article  PubMed  Google Scholar 

  35. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry. 1995;59:102–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Scaglione F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. Toxins (Basel). 2016;8(3):65.

    Article  PubMed Central  Google Scholar 

  37. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double-blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Shin JH, Jeon C, Woo KI, Kim YD. Clinical comparability of Dysport and Botox in essential blepharospasm. J Korean Ophthalmol Soc. 2009;50:331–5.

    Article  Google Scholar 

  39. Kollewe K, Mohammadi B, Köhler S, Pickenbrock H, Dengler R, Dressler D. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®. J Neural Transm. 2015;122(3):427–31.

    Article  CAS  PubMed  Google Scholar 

  40. Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Correia AP, et al. Dysport: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox, assuming a ratio of 4:1. Mov Disord. 1997;12(6):1013–8.

    Article  CAS  PubMed  Google Scholar 

  41. Nussgens Z. Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm. Arch Clin Exp Ophthalmol. 1997;235(4):197–9.

    Article  CAS  Google Scholar 

  42. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a doubleblind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2002;72(4):459–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Bentivoglio AR, Ialongo T, Bove F, de Nigris F, Fasano A. Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci. 2012;33:261–7.

    Article  PubMed  Google Scholar 

  44. Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775–83.

    Article  CAS  PubMed  Google Scholar 

  45. Bhatia KP, Münchau A, Thompson PD, Houser M, Chauhan VS, Hutchinson M, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry. 1999;67(1):90–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011;58(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  47. Roche N, Schnitzler A, Genet FF, Durand MC, Bensmail D. Undesirable distant effects following botulinum toxin type A injection. Clin Neuropharmacol. 2008;31(5):272280.

    Article  CAS  Google Scholar 

  48. Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon. 2009;54(5):683–9.

    Article  CAS  PubMed  Google Scholar 

  49. Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (N Y). 2012. https://doi.org/10.7916/D88W3C1M

    Article  Google Scholar 

  50. Aoki KR. Review of a proposed mechanism for the antinociceptive action of Abotulinum toxin type A. NeuroToxicology. 2005;26:785–93.

    Article  CAS  PubMed  Google Scholar 

  51. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett. 1995;201(1):37–40.

    Article  CAS  PubMed  Google Scholar 

  52. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005;26(1):26–31.

    Article  CAS  PubMed  Google Scholar 

  53. Varghese-Kroll E, Elovic EP. Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil. 2009;88(6):495–9.

    Article  PubMed  Google Scholar 

  54. Thomas AM, Simpson DM. Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve. 2012;46(3):443–8.

    Article  PubMed  Google Scholar 

  55. Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). J Med Econ. 2014;17(9):618–25.

    Article  PubMed  Google Scholar 

  56. Santamato A, Panza F, Ranieri M, Frisardi V, Micello MF, Filoni S, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm. 2013;120(3):469–76.

    Article  CAS  PubMed  Google Scholar 

  57. Intiso D, Simone V, Di Rienzo F, Iarossi A, Pazienza L, Santamato A, et al. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. NeuroRehabilitation. 2014;34:515–22.

    PubMed  Google Scholar 

  58. Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study. Neurology. 2017;88(14):1321–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Santamato A, Panza F, Intiso D, Baricich A, Picelli A, Smania N, et al. Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke. J Neurol Sci. 2017;378:182–6.

    Article  CAS  PubMed  Google Scholar 

  60. Sanders DB. Clinical impact of single-fiber electromyography. Muscle Nerve Suppl. 2002;11:S15–20.

    Article  PubMed  Google Scholar 

  61. Garner CG, Straube A, Witt TN, Gasser T, Oertel WH. Time course of distant effects of local injections of botulinum toxin. Mov Disord. 1993;8(1):33–7.

    Article  CAS  PubMed  Google Scholar 

  62. Erdal J, Ostergaard L, Fuglsang-Frederiksen A, et al. Long-term botulinum toxin treatment of cervical dystonia-EMG changes in injected and noninjected muscles. Clin Neurophysiol. 1999;110(9):1650–4.

    Article  CAS  PubMed  Google Scholar 

  63. Vita G, Girlanda P, Puglisi RM, Marabello L, Messina C. Cardiovascular reflex testing and single-fiber electromyography in botulism. A longitudinal study. Arch Neurol. 1987;44(2):202–6.

    Article  CAS  PubMed  Google Scholar 

  64. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 1981;213:220–2.

    Article  CAS  PubMed  Google Scholar 

  65. Pomeranz B, Macaulay RJ, Caudill MA, Kutz I, Adam D, Gordon D, et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol. 1985;248(1 Pt 2):H151–3.

    CAS  PubMed  Google Scholar 

  66. Kleiger RE, Bigger JT, Bosner MS, Chung MK, Cook JR, Rolnitzky LM, et al. Stability over time of variables measuring heart rate variability in normal subjects. Am J Cardiol. 1991;68(6):626–30.

    Article  CAS  PubMed  Google Scholar 

  67. Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996;94(11):2850–5.

    Article  CAS  PubMed  Google Scholar 

  68. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043–65.

    Article  Google Scholar 

  69. Wichterle D, Simek J, La Rovere MT, Schwartz PJ, Camm AJ, Malik M. Prevalent low-frequency oscillation of heart rate: novel predictor of mortality after myocardial infarction. Circulation. 2004;110(10):1183–90.

    Article  PubMed  Google Scholar 

  70. Girlanda P, Vita G, Nicolosi C, Milone S, Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry. 1992;55:844–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology. 1996;46:26–9.

    Article  CAS  PubMed  Google Scholar 

  72. Nebe A, Schelosky L, Wissel J, Ebersbach G, Scholz U, Poewe W. No effects on heart-rate variability and cardiovascular reflex tests after botulinum toxin treatment of cervical dystonia. Mov Disord. 1996;11:337–9.

    Article  CAS  PubMed  Google Scholar 

  73. Meichsner M, Reichel G. Effect of botulinum toxin A and B on vegetative cardiac innervation. Fortschr Neurol Psychiatr. 2005;73:409–14.

    Article  CAS  PubMed  Google Scholar 

  74. Tiple D, Strano S, Colosimo C, Fabbrini G, Calcagnini G, Prencipe M, et al. Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A. J Neurol. 2008;255:843–7.

    Article  CAS  PubMed  Google Scholar 

  75. Invernizzi M, Carda S, Molinari C, Stagno D, Cisari C, Baricich A. Heart rate variability (HRV) modifications in adult hemiplegic patients after botulinum toxin type A (NT-201) injection. Eur J Phys Rehabil Med. 2015;51(4):353–9.

    CAS  PubMed  Google Scholar 

  76. Baricich A, Grana E, Carda S, Santamato A, Molinari C, Cisari C, et al. Heart rate variability modifications induced by high doses of incobotulinumtoxinA and onabotulinumtoxinA in hemiplegic chronic stroke patients: a single blind randomized controlled, crossover pilot study. Toxicon. 2017;138:145–50.

    Article  CAS  PubMed  Google Scholar 

  77. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry. 1997;62(2):198.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Henzel MK, Munin MC, Niyonkuru C, Skidmore ER, Weber DJ, Zafonte RD. Comparison of surface and ultrasound localization to identify forearm flexor muscles for botulinum toxin injections. PM R. 2010;2(7):642–6.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Mayer NH, Simpson DM. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset muscle overactivity in patients with an upper motoneuron lesion. In: Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management and the role of botulinum toxin. 3rd ed. New York: We Move; 2005.

    Google Scholar 

  80. Ward AB, Wissel J, Borg J, Ertzgaard P, Herrmann C, Kulkarni J, et al. Functional goal achievement in post-stroke spasticity patients: the BOTOX® Economic Spasticity Trial (BEST). J Rehabil Med. 2014;46(6):504–13.

    Article  PubMed  Google Scholar 

  81. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000;69(2):217–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Zorowitz RD, Wein TH, Dunning K, Deltombe T, Olver JH, Davé SJ, et al. A screening tool to identify spasticity in need of treatment. Am J Phys Med Rehabil. 2017;96(5):315–20.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Leach E, Cornwell P, Fleming J, Haines T. Patient centered goal-setting in a subacute rehabilitation setting. Disabil Rehabil. 2010;32(2):159–72.

    Article  PubMed  Google Scholar 

  84. Sunnerhagen KS, Francisco GE. Enhancing patient–provider communication for long-term post-stroke spasticity management. Acta Neurol Scand. 2013;128:305–10.

    CAS  PubMed  Google Scholar 

  85. Baricich A, Picelli A, Molteni F, Guanziroli E, Santamato A. Post-stroke spasticity as a condition: a new perspective on patient evaluation. Funct Neurol. 2016;31(3):179–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Baricich A, Cosenza L, Sandrini G, Paolucci S, Morone G, Santamato A, et al. Development of a patient-centered questionnaire for post-stroke spasticity assessment: a reliability study. Funct Neurol. 2018;33(2):113–5.

    PubMed  Google Scholar 

  87. Walsh LD, Moseley GL, Taylor JL, Gandevia SC. Proprioceptive signals contribute to the sense of body ownership. J Physiol. 2011;589(Pt 12):3009–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Turner-Stokes L, Ashford S, Jacinto J, Maisonobe P, Balcaitiene J, Fheodoroff K. Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III). BMJ Open. 2016;6(6):e011157.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Lucrezia Moggio, MD for manuscript revision.

Author information

Authors and Affiliations

  1. Physical Medicine and Rehabilitation, Department of Health Sciences, Università del Piemonte Orientale, viale Piazza d’armi 1, 28100, Novara, Italy

    Alessio Baricich, Carlo Cisari & Marco Invernizzi

  2. Department of Neurological, Biomedical and Movement Sciences, Neuromotor and Cognitive Rehabilitation Research Center, University of Verona, Verona, Italy

    Alessandro Picelli & Nicola Smania

  3. Department of Physical Medicine and Rehabilitation, “OORR Hospital”, Università di Foggia, Foggia, Italy

    Andrea Santamato

  4. Neuropsychology and Neurorehabilitation Service, Department of Clinical Neuroscience, Lausanne University Hospital (CHUV), Lausanne, Switzerland

    Stefano Carda

  5. Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, Italy

    Alessandro de Sire

Authors
  1. Alessio Baricich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Picelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Santamato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefano Carda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alessandro de Sire
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicola Smania
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Carlo Cisari
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Marco Invernizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessio Baricich.

Ethics declarations

Funding

No funding was received to prepare this review.

Conflict of interest

Dr. Baricich received consulting fees and speaking honoraria from Allergan, Ipsen, and Merz. Dr. Picelli received consulting fees from Allergan and Ipsen and speaking honoraria from Allergan. Dr. Santamato received consulting fees from Allergan, Ipsen, and Merz. Prof. Smania received consulting fees from Allergan and Ipsen and speaking honoraria from Allergan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baricich, A., Picelli, A., Santamato, A. et al. Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment. Clin Drug Investig 38, 991–1000 (2018). https://doi.org/10.1007/s40261-018-0701-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0701-x

Search

Navigation